Accession Number:



Identifying New Chemical Entitites that Treat and Prevent Relapsing Vivax and Drug-Resistant Falciparum Malaria in U.S. Military Personnel

Descriptive Note:

Technical Report

Corporate Author:

Trustees of Columbia University in the City of New York New York United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Our project has now nearly completing the screening of 400,000 compounds from the National Center for AdvancingTranslational Sciences NCATS chemical library, for activity against Plasmodium falciparum asexual blood stages. To date wehave nearly 2,000 compounds that inhibit growth at low to submicromolar concentrations Nearly 600 of our prioritized hitcompounds have been tested against rodent malaria liver stages and we have a set of 43 active compounds that havepromising potency and selectivity from which to initiate in vivo assays to assess for cure and prophylaxis. We have also madeprogress with generating plasmids to engineer Plasmodium cynomolgi parasites that can be used to screen for activity againstliver stages in a model of relapsing malaria. We are on track with our goal to identify chemical series that can be tested ascandidate medicines to cure and prevent malaria in US Military personnel.

Subject Categories:

Distribution Statement: